NEW YORK (GenomeWeb News) – Entelos today said it has signed a contract with the Foundation for the National Institutes of Health Biomarkers Consortium to study and prioritize biomarkers of cardiovascular risk.
Simulations Plus is selling Words+, its computer-based communications systems subsidiary, so that it can focus on expanding its footprint in pharmaceutical markets, Walt Woltosz, the company's chairman and CEO, said this week.
By Uduak Grace Thomas
Simulations Plus said this week that it has submitted a bid to purchase all the assets of biosimulation software developer Entelos, which filed for Chapter 11 bankruptcy protection in July.
The web-based method, dubbed DRAR-CPI, compares query drugs to a library of 385 proteins and 254 small molecules to suggest new targets for old drugs and identify possible adverse reactions for candidate molecules.